Literature DB >> 993726

Antibody-mediated suppression of grafted lymphoma. IV. Influence of time of tumor residency in vivo and tumor size upon the effectiveness of suppression by syngeneic antibody.

H S Shin, J S Economou, G R Pasternack, R J Johnson, M L Hayden.   

Abstract

In the suppression of the growth of a mouse lymphoma 6C3HED by antibody, the effectiveness of antibody in suppressing growing or established tumor cells and comparable number of freshly injected tumor cells is quantitatively similar. The effectiveness of antibody diminishes markedly when the number of tumor cells per mouse reaches the level of 10(6) due to the development of a macrophage shortage. At the 10(5) tumor cells level, antibody-mediated suppression takes place in an optimal manner and between 10(5) and 10(4) tumor cell numbers, the amount of antibody required to suppress 50% of the tumor cells is directly proportional to the number of tumor cells suppressed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 993726      PMCID: PMC2190456          DOI: 10.1084/jem.144.5.1274

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  14 in total

1.  Immune mechanisms in homotransplantation. I. The role of serum antibody and complement in the neutralization of lymphoma cells.

Authors:  H J WINN
Journal:  J Immunol       Date:  1960-05       Impact factor: 5.422

2.  Inhancement activity of mouse immunoglobulin classes.

Authors:  G L Irvin; J C Eustace; J L Fahey
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

Review 3.  Cytotoxic effects of lymphoid cells in vitro.

Authors:  P Perlmann; G Holm
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

4.  Antibody-mediated in vivo suppression of EL4 leukemia in a syngeneic host.

Authors:  J Zighelboim; B Bonavida; J L Fahey
Journal:  J Natl Cancer Inst       Date:  1974-03       Impact factor: 13.506

5.  Immunochemical and biologic characterization of alloantibody active in immunologic enhancement.

Authors:  T C Fuller; H J Winn
Journal:  Transplant Proc       Date:  1973-03       Impact factor: 1.066

6.  Subversion of host defense mechanisms by murine tumors. I. A circulating factor that suppresses macrophage-mediated resistance to infection.

Authors:  R J North; D P Kirstein; R L Tuttle
Journal:  J Exp Med       Date:  1976-03-01       Impact factor: 14.307

7.  Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts.

Authors:  H S Shin; M Hayden; S Langley; N Kaliss; M R Smith
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

8.  Antiinflammatory effects of murine malignant cells.

Authors:  R M Fauve; B Hevin; H Jacob; J A Gaillard; F Jacob
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

9.  Quantitative studies on tumor enhancement in mice. I. Enhancement of sarcoma I induced by IgM, IgG1, and IgG2.

Authors:  P Rubinstein; F Decary; E W Streun
Journal:  J Exp Med       Date:  1974-08-01       Impact factor: 14.307

10.  IgM-induced tumor cell cytotoxicity mediated by normal thymocytes.

Authors:  E W Lamon; H D Whitten; B Lidin; H H Fudenberg
Journal:  J Exp Med       Date:  1975-08-01       Impact factor: 14.307

View more
  4 in total

1.  Time-dependent resistance or susceptibility of tumor cells to cytotoxic antibody after exposure to a chemotherapeutic agent.

Authors:  P J Leibson; H Schreiber; M R Loken; S Panem; D A Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

2.  Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells.

Authors:  D Berends; T H van der Kwast; N J de Both; P G Mulder
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Effect of host immune status on the spontaneous metastasis of cloned cell lines of the 13762NF rat mammary adenocarcinoma.

Authors:  S M North; G L Nicolson
Journal:  Br J Cancer       Date:  1985-11       Impact factor: 7.640

4.  Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen.

Authors:  C C Badger; I D Bernstein
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.